My daughter died of AML earlier this year. AML is unfortunately much harder to treat than ALL. She was treated for almost three years (it came back twice). We "lived" with her in the hospital for around 1,5 years over that three year period.
Many of the chemo medications she got have been a stable of AML treatment for decades. From what I understood from our doctors, the improvement in survival rate for AML has come from supportive care, i.e. the ability to keep the patient alive during treatment. Treatment of bacterial and fungal infections has gotten a lot better.
AML is a very heterogeneous disease. The treatment depends a lot on the specific mutations the patient has. Research can only focus on so many target mutations at a time. We did see the progress over the three years we were there. I have high hopes that children with the same mutation as my daughter will in the near future have better chances, specifically thanks to menin inhibitors.
Many of the chemo medications she got have been a stable of AML treatment for decades. From what I understood from our doctors, the improvement in survival rate for AML has come from supportive care, i.e. the ability to keep the patient alive during treatment. Treatment of bacterial and fungal infections has gotten a lot better.
AML is a very heterogeneous disease. The treatment depends a lot on the specific mutations the patient has. Research can only focus on so many target mutations at a time. We did see the progress over the three years we were there. I have high hopes that children with the same mutation as my daughter will in the near future have better chances, specifically thanks to menin inhibitors.